
FDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product
A Johnson & Johnson autoimmune disease medicine that’s a relative latecomer in its drug class can now compete in its first FDA-approved indication with a label that covers a broader patient population than products already available from Argenx and UCB …